ROKIT HEALTHCARE obtains European certification for organ regeneration technology
Monday, August 14, 2023
ROKIT HEALTHCARE, a pioneering biotechnology company specializing in advanced organ regeneration, today announces the end of a major milestone in its business. In July 2023, the company obtained the desired certification confirming compliance with the European Medical Devices Regulation (CE marking in accordance with MDR) for the revolutionary Dr Invivo AI Regen platform. This certificate emphasizes ROKIT's commitment to the development of medical technologies and the treatment of patients.
The Dr Invivo AI Regen platform represents a huge advancement in organ regeneration and medical device innovation by combining artificial intelligence technology with bioprinting. This groundbreaking approach produces exceptional results in the short term with no response from the immune system, revolutionizing organ regeneration.
The heart of the platform is the state-of-the-art artificial intelligence technology, which allows for the identification of affected areas, translating this data into code files, which are the basis for bioprinting. Using the patient's adipose tissue, the kit generates a piece of specialized tissue for transplantation. This method aims to treat chronic wounds, such as diabetic foot ulcers, redefining the regeneration of skin tissue. Involvement in the treatment of the diabetic foot has led to research carried out in many countries, supported by publications in renowned scientific journals included in the citation index.
Thanks to approvals issued by medical agencies, including the U.S. Food and Drug Administration (FDA) and the South Korean Ministry of Food and Drug Safety, Dr. Invivo AI Regen has gained worldwide recognition. The platform is exported to ten countries, including the US , and the recent CE certification for medical devices has paved the way for ROKIT HEATHCARE to conquer developed markets.
The importance of CE MDR certification lies in the stringent standards for the sale of medical devices in Europe, in accordance with the regulation that replaced the Medical Devices Directive (MDD CE). Certified products can be marketed in 31 countries, including the countries of the European Economic Area (EEA) and the European Union (EU). Europe is at the forefront of the regenerative medicine sector, with growth of 10% per year.
SeokHwan You, CEO of ROKIT HEALTHCARE, said, "This certification drives our growth in markets around the world, allowing us to expand the availability of advanced medical technology." As a leader in regenerative medicine, the company is developing regenerative medicine and AI-powered bioprinting technologies.
Established in 2012, ROKIT HEATHCARE, a member of the Born2Global Center, is a pioneer in the field of regenerative medicine based on artificial intelligence and bioprinting. Cooperating with the Seoul National University Hospital (SNUH) and the Asan Hospital, he undertakes activities in the field of chronic kidney failure treatment methods.
Source: prnewswire.com